

PCT

WORLD INTELLECTUAL PROPERTY  
ORGANIZATION  
International I

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9605825A1

(51) International Patent Classification 6 : <b>A61K 31/38</b>		A1	(11) International Publication Number: <b>WO 96/05825</b>
			(43) International Publication Date: 29 February 1996 (29.02.96)
(21) International Application Number: PCT/US95/10618 (22) International Filing Date: 21 August 1995 (21.08.95) (30) Priority Data: 08/294,130                  22 August 1994 (22.08.94)                  US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors: CULLINAN, George, Joseph; R.R. 1, Box 468, Trafalgar, IN 46181 (US). SATO, Masahiko; 96 Hawthorne Drive, Carmel, IN 46033 (US). (74) Agent: LAMMERT, Steven, R.; Barnes & Thornburg, 1313 Merchants Bank Building, Indianapolis, IN 46204 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  Published With international search report.	
(54) Title: METHODS FOR BONE HEALING AND FRACTURE REPAIR			
<div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;"> <math display="block">\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-(\text{C}_1-\text{C}_6 \text{ alkyl}) \end{array} \quad (a)</math> </div> <div style="text-align: center;"> <math display="block">\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{Ar} \end{array} \quad (b)</math> </div> </div>			
(57) Abstract <p>A method of facilitating bone healing and fracture repair comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R<sup>1</sup> and R<sup>3</sup> are independently hydrogen, -CH<sub>3</sub>, (a), or (b), wherein Ar is optionally substituted phenyl; R<sup>2</sup> is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


## METHODS FOR BONE HEALING AND FRACTURE REPAIR

Approximately, 20-25 million women and an increasing  
5 number of men have detectable vertebral fractures, with an  
additional 250,000 hip fractures reported yearly in America  
alone. The latter case is associated with a 12% mortality  
rate within the first two years and with a 30% rate of  
patients requiring nursing home care after the fracture.  
10 While this is already significant, the economic and medical  
consequences of convalescence due to slow or imperfect  
healing of these bone fractures is expected to increase,  
due to the aging of the general population. While there  
are several promising therapies (bis-phosphonates,  
15 Tamoxifen, etc.) in development to prevent bone loss with  
age and thus reduce the probability of incurring  
debilitating fractures, these therapies are not indicated  
for treatment once the fracture has occurred.

Estrogens have been shown (Bolander et al., 38th  
20 Annual Meeting Orthopedic Research Society, 1992) to  
improve the quality of the healing of appendicular  
fractures. Therefore, estrogen replacement therapy would  
appear to be a method for the treatment of fracture repair,  
as it is for post-menopausal osteoporosis. However,  
25 patient compliance with estrogen therapy is relatively poor  
due to its side effects, including the resumption of  
menses, mastodynia, an increased risk of uterine cancer, an  
increased perceived risk of breast cancer, and the  
concomitant use of progestins. In addition, men are likely  
30 to object to the use of estrogen treatment. Clearly the  
need exists for a therapy which would be beneficial to  
patients who have suffered debilitating bone fractures and  
which would increase patient compliance.

-2-

This invention provides methods of facilitating bone healing and fracture repair comprising administering to a human in need thereof an effective amount of a compound of formula I



wherein R¹ and R³ are independently hydrogen,

10 -CH₃,  $\text{-}\overset{\text{O}}{\parallel}\text{C-}(\text{C}_1\text{-C}_6 \text{ alkyl})$ , or  $\text{-}\overset{\text{O}}{\parallel}\text{C-Ar}$ , wherein Ar is optionally substituted phenyl;

R² is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.

15

The current invention concerns the discovery that a select group of 2-phenyl-3-arylbenzothiophenes (benzothiophenes), those of formula I, are useful for facilitating bone healing and fracture repair. Raloxifene and selected analogs are nuclear regulators which share certain physiological effects with estrogens, particularly in bone homeostasis, but are essentially devoid of the uterine and breast effects of estrogens. Additionally, raloxifene has a greatly reduced potential for feminization in men than estrogens.

20

The therapeutic and prophylactic, such as given prior to surgery requiring or causing bone damage, treatments provided by this invention are practiced by

25

-3-

administering to a human in need thereof a dose of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, that is effective to facilitate bone healing or fracture repair.

5               Raloxifene is a preferred compound of this invention and it is the hydrochloride salt of a compound of formula 1 wherein R<sup>1</sup> and R<sup>3</sup> are hydrogen and R<sup>2</sup> is 1-piperidinyl.

10               Generally, at least one compound of formula I is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes. The compounds can be administered transdermally, and may be  
15               formulated as sustained release dosage forms and the like.

              The compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent Nos. 4,133,814, 4,418,068, and 4,380,635 all of which are incorporated by  
20               reference herein. In general, the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group. The starting compound is protected, acylated, and deprotected to form the formula I compounds. Examples of the preparation of such compounds are provided  
25               in the U.S. patents discussed above. The term "optionally substituted phenyl" includes phenyl and phenyl substituted once or twice with C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, hydroxy, nitro, chloro, fluoro, or tri(chloro or fluoro)methyl.

              The compounds used in the methods of this  
30               invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. Typical  
35               inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric,

phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanolic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate,  $\beta$ -hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like. A preferred salt is the hydrochloride salt.

The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.

Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth

-5-

metal hydroxides, carbonates, as well as aliphatic and primary, secondary and tertiary amines, aliphatic diamines. Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylene diamine and cyclohexylamine.

The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.

Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.

The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular

part of the intestinal tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.

5 The particular dosage of a compound of formula I required to facilitate bone healing and fracture repair, according to this invention, will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician. Generally, accepted and effective daily doses will be from  
10 about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be administered to a subject in need thereof from once to about three times each day, or more often as needed, and for a duration, to effectively treat the patient.

15 It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino ring. For such purposes the following oral dosage forms are available.

20

#### Formulations

In the formulations which follow, "Active ingredient" means a compound of formula I.

25 Formulation 1: Gelatin Capsules

Hard gelatin capsules are prepared using the following:

Ingredient	Quantity (mg/capsule)
Active ingredient	0.1 - 1000
Starch, NF	0 - 650
Starch flowable powder	0 - 650
Silicone fluid 350 centistokes	0 - 15



-7-

The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.

Examples of specific capsule formulations of raloxifene that have been made include those shown below:

5

Formulation 2: Raloxifene capsule

<u>Ingredient</u>	<u>Quantity (mg/capsule)</u>
Raloxifene	1
Starch, NF	112
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7

Formulation 3: Raloxifene capsule

10

<u>Ingredient</u>	<u>Quantity (mg/capsule)</u>
Raloxifene	5
Starch, NF	108
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7

Formulation 4: Raloxifene capsule

<u>Ingredient</u>	<u>Quantity (mg/capsule)</u>
Raloxifene	10
Starch, NF	103
Starch flowable powder	225.3
Silicone fluid 350 centistokes	1.7

-8-

Formulation 5: Raloxifene capsule

<u>Ingredient</u>	<u>Quantity (mg/capsule)</u>
Raloxifene	50
Starch, NF	150
Starch flowable powder	397
Silicone fluid 350 centistokes	3.0

5           The specific formulations above may be changed  
in compliance with the reasonable variations provided.

A tablet formulation is prepared using the  
ingredients below:

Formulation 6: Tablets

10

<u>Ingredient</u>	<u>Quantity (mg/tablet)</u>
Active ingredient	0.1 - 1000
Cellulose, microcrystalline	0 - 650
Silicon dioxide, fumed	0 - 650
Stearate acid	0 - 15

The components are blended and compressed to form tablets.

Alternatively, tablets each containing 0.1 -  
1000 mg of Active ingredient are made up as follows:

Formulation 7: Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	0.1 - 1000
Starch	45
Cellulose, microcrystalline	35
Polyvinylpyrrolidone (as 10% solution in water)	4
Sodium carboxymethyl cellulose	4.5
Magnesium stearate	0.5
Talc	1

5 The active ingredient, starch, and cellulose are  
passed through a No. 45 mesh U.S. sieve and mixed  
thoroughly. The solution of polyvinylpyrrolidone is mixed  
with the resultant powders which are then passed through a  
No. 14 mesh U.S. sieve. The granules so produced are dried  
at 50°-60° C and passed through a No. 18 mesh U.S. sieve.  
10 The sodium carboxymethyl starch, magnesium stearate, and  
talc, previously passed through a No. 60 U.S. sieve, are  
then added to the granules which, after mixing, are  
compressed on a tablet machine to yield tablets.

15 Suspensions each containing 0.1 - 1000 mg of  
Active ingredient per 5 mL dose are made as follows:

Formulation 8: Suspensions

Ingredient	Quantity (mg/5 ml)
Active ingredient	0.1 - 1000 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mg
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to	5 mL

-10-

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

### ASSAYS

#### Assay 1

Six month old, virgin Sprague-Dawley female rats (Harlan, IN) weighing about 270g are maintained on a 12 hr light/dark cycle at 22°C with ad lib access to food (TD 89222 with 0.5% Ca and 0.4% P, Teklad, Madison, WI) and water. Bilateral ovariectomies are performed for multiple sets of rats, except for SHAM controls, at 6 months of age. Rats are grouped into treatment units of n=9 per set and orally dosed daily for 28 days to include: 1) sham-operated control (SHAM), 2) ovariectomized control (OVX), 3) OVX treated with a compound of formula 1. The proximal tibiae are scanned longitudinally to confirm ovariectomy induced bone loss and efficacy of treatment. Multiple sets of rats are followed longitudinally to yield about 200 rats per group by the end of the study.

At 28 days post-ovariectomy, both femora are pinned and one of the femora is fractured, as described in Bonnarens et al., 1984, J. Orthopaedic Research 2:97-101. Transverse fractures are compared to pinned controls by x-ray analysis, and daily dosing of rats is continued for an additional 42 days. Fracture calluses are collected at days 1-14 post-fracture and harvested for RNA to probe for treatment effects on the expression of specific genes by Northern analysis. At 70 days post-ovariectomy, the remaining rats are sacrificed to collect serum for cholesterol analysis, uteri to confirm efficacy of ovariectomy, both femora, and contralateral tibia for bone mass analysis by QCT. Both fractured and contralateral

-11-

femora are x-rayed and biomechanically tested by torsional analysis to examine treatment effects on fracture healing, relative to contralateral controls. End points evaluated include treatment effects on TGF- $\beta$  and estrogen receptor gene expression, x-ray analysis of fractures, bone mass measurements longitudinally and cross-sectionally, and biomechanical analysis for fractures.

#### Assay 2


Five to fifty women are selected for the clinical study. The women have experienced bone damage, such as a fracture that has been initially treated in the conventional manner, ie., resetting the bone, immobilization, or surgical procedure. The study has a placebo control group, i.e., the women are divided into two groups, one of which receives a compound of formula 1 as the active agent and the other receives a placebo. Women in the test group receive between 50-200 mg of the drug per day. They continue this therapy for 1-6 months. Accurate records are kept as to the status of the fracture repair. The results are compared both between members of each group and also the results for each patient are compared reported by each patient before the study began.

Utility of the compounds of formula I is illustrated by the positive impact they have in at least one of the assays described above.

-12-

We claim:

1. A method of facilitating bone healing or fracture repair comprising administering to a human in need thereof an effective amount of a compound having the formula



(I)


wherein R<sup>1</sup> and R<sup>3</sup> are independently hydrogen, -CH<sub>3</sub>,  $\text{-}\overset{\text{O}}{\parallel}\text{C}\text{-(C}_1\text{-C}_6\text{ alkyl)}$ , or  $\text{-}\overset{\text{O}}{\parallel}\text{C-Ar}$ , wherein Ar is optionally substituted phenyl;

R<sup>2</sup> is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

2. The method of Claim 1 wherein said compound is the hydrochloride salt thereof.

3. The method of Claim 1 wherein said administration is prophylactic.

4. The method of Claim 1 wherein said compound is



5

or its hydrochloride salt.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/10618

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/38

US CL :514/443

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/443

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

SEARCH TERMS: AROYLBENZOTHIOPHENE? AND BONE AND HEALING AND FRACTURE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,133,814 (JONES ET AL.) 09 JANUARY 1979, COLUMN 1, LINE 10 TO COLUMN 2, LINE 3.	1-4
A	US, A, 4,418,068 (JONES) 29 NOVEMBER 1983, COLUMN 1, LINE 10 TO COLUMN 2 LINE 47.	1-4

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"U"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"A"	document member of the same patent family

Date of the actual completion of the international search 26 SEPTEMBER 1995	Date of mailing of the international search report 12 OCT 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer THEODORE J. CRIARES Telephone No. (703) 308-1235